A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin DeficiencyAssociatedLiver Disease With METAVIR Stage F2 to F4 Fibrosis
The Redwood Study for Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Sponsor: Takeda Development Center Americas, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU4096
U.S. Govt. ID: NCT05677971
Contact: Transplant Clinical Research Center TCRC: / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to determine how safe and effective fazirsiran is in patients with alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD) compared to placebo. Eligible participants will receive either fazirsiran or placebo for about 4 years. This is a double-blind study, so the study doctors and participants will not know whether or not they are receiving fazirsiran or placebo. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Dana Goldner, MD
Do You Qualify?
Are you between 18 and 75 years old? Yes No
Do you have a diagnosis of alpha-1 antitrypsin deficiency (AATD)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Transplant Clinical Research Center TCRC